AR036604A1 - Derivados de 4-pirimidona 3-sustituida - Google Patents

Derivados de 4-pirimidona 3-sustituida

Info

Publication number
AR036604A1
AR036604A1 ARP020103547A ARP020103547A AR036604A1 AR 036604 A1 AR036604 A1 AR 036604A1 AR P020103547 A ARP020103547 A AR P020103547A AR P020103547 A ARP020103547 A AR P020103547A AR 036604 A1 AR036604 A1 AR 036604A1
Authority
AR
Argentina
Prior art keywords
substituted
ring
alkyl group
atom
group
Prior art date
Application number
ARP020103547A
Other languages
English (en)
Inventor
Fumiaki Uehara
Aya Shoda
Shinsuke Hiki
Masahiro Okuyama
Mitsuru Ooizumi
Kazutoshi Watanabe
Yoshihiro Usui
Keiichi Aritomo
Original Assignee
Mitsubishi Pharma Corp
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp, Sanofi Synthelabo filed Critical Mitsubishi Pharma Corp
Publication of AR036604A1 publication Critical patent/AR036604A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Un derivado de pirimidona representado por la fórmula (1) o una sal del mismo, o un solvato del mismo, o un hidrato del mismo que tiene una actividad inhibidora contra la cinasa proteínica tau 1. También se reivindican un medicamento y un inhibidor de la cinasa proteínica tau 1. Dicho medicamento se usa para el tratamiento preventivo y/o terapéutico de una enfermedad causada por la hiper actividad de la cinasa proteínica tau 1, tales como: mal de Alzheimer, accidentes cerebrovasculares isquémicos, síndrome de Down, complejo de demencia y parkinsonismo de Guam, demencia vascular, danos traumáticos, traumas cerebrales y de la médula espinal, retinopatía y glaucoma. Reivindicación 1: Un derivado de pirimidona representado por la fórmula (1) o una sal del mismo, o un solvato del mismo, o un hidrato del mismo, caracterizada porque R1 representa un grupo alquilo C1-12 que puede ser sustituido; R representa cualquiera de los grupos representados por las siguientes fórmulas (2) a (5) caracterizadas porque R2 y R3 independientemente representan un átomo de hidrógeno o un grupo alquilo C1-8; R4 representa un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, un anillo de indano que puede ser sustituido, un anillo de tetrahidronaftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y tiene de 5 a 10 átomos, en total. R5 representa un grupo alquilo C1-8 que puede ser sustituido, un grupo cicloalquilo C3-8 que puede ser sustituido, un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, un anillo de indano que puede ser sustituido, un anillo de tetrahidronaftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y tiene de 5 a 10 átomos, en total. R6 representa un átomo de hidrógeno, un grupo alquilo C1-8 que puede ser sustituido, un anillo de benceno que puede ser sustituido; ó R5 y R6 pueden unirse para formar, junto con el carbono al cual se unen, un anillo espiro cíclico opcionalmente sustituido, que tiene de 3 a 11 átomos, en total, que constituyen el anillo; R7 y R8 independientemente representan un átomo de hidrógeno, o un grupo alquilo C1-8, o R7 y R8 pueden combinarse para formar un grupo alquileno C2-6; R9 y R10 representan un grupo alquilo C1-8 que puede ser sustituido, un grupo cicloalquilo C3-8 que puede ser sustituido, un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y tiene de 5 a 10 átomos, en total, o R9 y R10 representan -N(R11)R12) caracterizados porque R11 representa un átomo de hidrógeno, un grupo alquilo C1-8; y R12 representa un grupo alquilo C1-8, un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y que tiene de 5 a 10 átomos en total, que constituyen el anillo; y X representa CH2, O ó NR13 caracterizados porque R13 representa un átomo de hidrógeno o un grupo alquilo C1-8.
ARP020103547A 2001-09-21 2002-09-20 Derivados de 4-pirimidona 3-sustituida AR036604A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001331675 2001-09-21
JP2001331678 2001-09-21
JP2001331676 2001-09-21
JP2001331674 2001-09-21

Publications (1)

Publication Number Publication Date
AR036604A1 true AR036604A1 (es) 2004-09-22

Family

ID=27482650

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020103546A AR043700A1 (es) 2001-09-21 2002-09-20 Derivados de 3-substituida-4-pirimidona
ARP020103547A AR036604A1 (es) 2001-09-21 2002-09-20 Derivados de 4-pirimidona 3-sustituida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP020103546A AR043700A1 (es) 2001-09-21 2002-09-20 Derivados de 3-substituida-4-pirimidona

Country Status (24)

Country Link
US (1) US7572793B2 (es)
EP (1) EP1427709B1 (es)
JP (1) JP4368682B2 (es)
KR (1) KR100754596B1 (es)
CN (1) CN1319950C (es)
AR (2) AR043700A1 (es)
AT (1) ATE312827T1 (es)
AU (1) AU2002337498B2 (es)
BR (1) BR0212893A (es)
CA (1) CA2460177C (es)
CY (1) CY1105554T1 (es)
DE (1) DE60208051T2 (es)
DK (1) DK1427709T3 (es)
EA (1) EA007224B1 (es)
ES (1) ES2256540T3 (es)
HK (1) HK1068608A1 (es)
HU (1) HUP0401898A3 (es)
IL (2) IL160701A0 (es)
MX (1) MXPA04002661A (es)
NO (1) NO326694B1 (es)
NZ (1) NZ531637A (es)
PL (1) PL368816A1 (es)
TW (1) TWI303171B (es)
WO (1) WO2003027080A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR023052A1 (es) 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
EA007576B1 (ru) 2001-09-21 2006-12-29 Мицубиси Фарма Корпорейшн Производные 3-замещенных 4-пиримидонов
MXPA05006394A (es) * 2002-12-16 2007-04-16 Mitsubishi Pharma Corp Derivados de 4-pirimidona 3-sustituida.
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
BRPI0413452A (pt) * 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AU2004318013B8 (en) 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200621760A (en) * 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
NZ554722A (en) 2004-09-29 2010-07-30 Mitsubishi Tanabe Pharma Corp 6-(Pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
EP2805953B1 (en) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
ES2373587T3 (es) * 2006-08-23 2012-02-06 Pfizer Products Inc. Compuestos de pirimidona como inhibidores de gsk-3.
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2009035159A1 (en) 2007-09-14 2009-03-19 Mitsubishi Tanabe Pharma Corporation 3-methyl-2- ( (2s) -2- (4- (3-methyl-l, 2, 4-0xadiaz0l-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor
BRPI0816705A2 (pt) 2007-09-14 2015-03-17 Mitsubishi Tanabe Pharma Corp Derivatido de 6-pirimidinil-pirimid-2-ona
EP2078717A1 (en) 2008-01-11 2009-07-15 sanofi-aventis 6-Pyrimidinyl-pyrimid-2-one derivative
AR076014A1 (es) * 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
JP5535310B2 (ja) * 2009-08-13 2014-07-02 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
JP5442852B2 (ja) 2009-08-13 2014-03-12 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
EP2550361B1 (en) 2010-03-25 2017-02-08 The J. David Gladstone Institutes Compositions and methods for treating neurological disorders
US9272055B2 (en) 2011-04-21 2016-03-01 The Regents Of The University Of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
ES2554843T3 (es) * 2012-01-12 2015-12-23 F. Hoffmann-La Roche Ag Derivados heterocíclicos como receptores asociados de trazas de amina (TAARs)
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
JP6543572B2 (ja) 2012-11-02 2019-07-10 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
DK3007726T3 (da) 2013-06-10 2020-07-06 Ipierian Inc Fremgangsmåder til behandling af en tauopati

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US187004A (en) * 1877-02-06 Improvement in water-wheels
JPS559099B2 (es) 1972-08-07 1980-03-07
JPS4935633A (es) 1972-08-09 1974-04-02
JPS4935632A (es) 1972-08-10 1974-04-02
JPS5124008B2 (es) 1972-08-10 1976-07-21
JPS5271481A (en) 1975-12-10 1977-06-14 Yoshitomi Pharmaceut Ind Ltd Synthesis of pyridylpyrimidines
JPS52139085A (en) 1976-05-13 1977-11-19 Hokuriku Pharmaceutical 22allylpiperazine derivative and method for its preparation
US4507302A (en) 1979-03-19 1985-03-26 The Upjohn Company Method for treating arthritis with 6-aryl pyrimidine compounds
US4619933A (en) 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
US4725600A (en) 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
ATE107633T1 (de) * 1988-04-22 1994-07-15 Zeneca Ltd Pyrimidinon-derivate.
DE58908208D1 (de) 1988-07-29 1994-09-22 Ciba Geigy Ag Thiouracile als Stabilisatoren für chlorhaltige Polymerisate.
DK0618968T3 (da) 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
DE4206145A1 (de) 1992-02-28 1993-09-02 Basf Ag Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide
JP3324611B2 (ja) 1992-07-03 2002-09-17 三菱化学株式会社 タウ蛋白質のリン酸化方法
JPH06329551A (ja) 1993-03-22 1994-11-29 Mitsubishi Kasei Corp アルツハイマー病の予防または治療薬およびそのスクリーニング方法
BR9407799A (pt) 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
HUP0001698A3 (en) 1996-12-05 2002-07-29 Amgen Inc Thousand Oaks Substituted pyrimidine compounds and their use
HUP0001140A3 (en) 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
EP0976745B1 (en) * 1997-03-26 2003-08-13 Taisho Pharmaceutical Co., Ltd 4-tetrahydropyridylpyrimidine derivatives
AR023052A1 (es) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
EP1261327B1 (en) 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
AU2001262150A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(nitrogen-heterocyclic)pyrimidone derivatives
EP1136482A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EA007576B1 (ru) 2001-09-21 2006-12-29 Мицубиси Фарма Корпорейшн Производные 3-замещенных 4-пиримидонов
MXPA05006394A (es) 2002-12-16 2007-04-16 Mitsubishi Pharma Corp Derivados de 4-pirimidona 3-sustituida.
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
EP1427709A1 (en) 2004-06-16
TWI303171B (en) 2008-11-21
DE60208051D1 (de) 2006-01-19
CA2460177C (en) 2010-03-23
NO20041604L (no) 2004-06-17
DE60208051T2 (de) 2006-06-22
KR100754596B1 (ko) 2007-09-05
PL368816A1 (en) 2005-04-04
CY1105554T1 (el) 2010-07-28
IL160701A (en) 2009-06-15
MXPA04002661A (es) 2004-11-22
KR20040054690A (ko) 2004-06-25
EA200400452A1 (ru) 2004-08-26
EP1427709B1 (en) 2005-12-14
CN1319950C (zh) 2007-06-06
ATE312827T1 (de) 2005-12-15
JP4368682B2 (ja) 2009-11-18
HUP0401898A3 (en) 2005-08-29
US7572793B2 (en) 2009-08-11
HK1068608A1 (en) 2005-04-29
AU2002337498B2 (en) 2006-08-10
JP2005510472A (ja) 2005-04-21
BR0212893A (pt) 2004-08-03
ES2256540T3 (es) 2006-07-16
AR043700A1 (es) 2005-08-10
WO2003027080A1 (en) 2003-04-03
CN1555367A (zh) 2004-12-15
DK1427709T3 (da) 2006-04-03
NZ531637A (en) 2005-12-23
US20050130967A1 (en) 2005-06-16
IL160701A0 (en) 2004-08-31
HUP0401898A2 (hu) 2004-12-28
EA007224B1 (ru) 2006-08-25
CA2460177A1 (en) 2003-04-03
NO326694B1 (no) 2009-02-02

Similar Documents

Publication Publication Date Title
AR036604A1 (es) Derivados de 4-pirimidona 3-sustituida
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR079541A1 (es) Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms
RU2007149317A (ru) Циклическое производное амина, содержащее замещенную алкильную группу
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
AR050180A1 (es) Derivados de guanidina y sus usos terapeuticos
AR040498A1 (es) Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias
AR032436A1 (es) Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro
BRPI0616574A2 (pt) derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
PE20010130A1 (es) Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion
DK1942108T3 (da) Forbindelse indeholdende basisk gruppe samt anvendelse deraf
RU2006130000A (ru) Органические соединения
RU2008107733A (ru) Ингибиторы gsk-3
CO5640104A2 (es) Derivados de aminoisoxazol activos como inhibidores de quinasa
AR057906A1 (es) Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta.
AR066972A1 (es) Derivados azapeptidicos
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
UY28787A1 (es) Derivados de beta-aminoacidos como inhibidores del factor xa
AR035651A1 (es) Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion
AR061583A1 (es) Acidos 6-(bencilo sustituido con heterociclil)-4-oxiquinolin carboxilicos, inhibidores de vih-integrasas, composiciones farmaceuticas que los contienen y usos como agentes anti-vih.
AR084430A1 (es) Di/tri-aza-espiro-alcanos c
AR063577A1 (es) Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos

Legal Events

Date Code Title Description
FG Grant, registration